Patents by Inventor Bhaumik Pandya

Bhaumik Pandya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and uses thereof
    Patent number: 12268687
    Abstract: The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: April 8, 2025
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Iwona Wrona, Kerem Ozboya, Matthew Lucas, Bhaumik Pandya, Bertrand Le Bourdonnec
  • PEPTIDE LIGANDS FOR CNS AND OCULAR DELIVERY OF RNAI COMPOUNDS
    Publication number: 20250075217
    Abstract: The disclosure relates to RNA agents targeting LRP1 receptor modified for targeted delivery to the brain and/or the eye. The present invention provides modified double stranded ribonucleic acid (dsRNAi) agents conjugated to a peptide ligand, as well as methods of modulating the expression of a target gene in a CNS cell or tissue and/or an ocular cell or tissue and methods of treating subjects having a CNS and/or an ocular disease or disorder using such dsRNAi agents.
    Type: Application
    Filed: July 29, 2022
    Publication date: March 6, 2025
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: JAYAPRAKASH K. NAIR, BHAUMIK A. PANDYA, SCOTT P. LENTINI, RYAN MALONE, HAIYAN PENG, ELENA CASTELLANOS-RIZALDOS, CHRISTOPHER S. THEILE, SHIGEO MATSUDA, MARTIN A. MAIER, VASANT R. JADHAV, KEVIN FITZGERALD, MARK NEIL TOLENTINO, IVAN ZLATEV
  • HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE
    Publication number: 20250042897
    Abstract: The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).
    Type: Application
    Filed: November 9, 2022
    Publication date: February 6, 2025
    Applicant: Vigil Neuroscience, Inc.
    Inventors: Jonathan B. HOUZE, Bhaumik PANDYA, Alan P. KAPLAN, Maxence BOS, John MANCUSO, Ivan FRANZONI
  • COMPOUNDS AND USES THEREOF
    Publication number: 20250034124
    Abstract: The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
    Type: Application
    Filed: September 20, 2024
    Publication date: January 30, 2025
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Iwona WRONA, Kerem OZBOYA, Matthew LUCAS, Bhaumik PANDYA, Bertrand LE BOURDONNEC
  • COMPOUNDS AND USES THEREOF
    Publication number: 20250034125
    Abstract: The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
    Type: Application
    Filed: September 20, 2024
    Publication date: January 30, 2025
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Iwona WRONA, Kerem OZBOYA, Matthew LUCAS, Bhaumik PANDYA, Bertrand LE BOURDONNEC
  • DEUTERATED DERIVATIVES OF RUXOLITINIB
    Publication number: 20250025467
    Abstract: The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.
    Type: Application
    Filed: October 3, 2024
    Publication date: January 23, 2025
    Inventors: I. Robert SILVERMAN, Julie F. LIU, Adam J. MORGAN, Bhaumik PANDYA, Scott L. HARBESON
  • Compounds and uses thereof
    Patent number: 12180221
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: December 31, 2024
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Bertrand Le Bourdonnec, Matthew Lucas, Kerem Ozboya, Bhaumik Pandya, Parcharee Tivitmahaisoon, Iwona Wrona
  • iRNA Compositions and Methods for Targeting ANGPTL7
    Publication number: 20240409943
    Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting ANGPTL7. The invention also relates to methods of using such dsRNA compositions to inhibit expression of ANGPTL7 and to methods of treating ANGPTL7-associated disorders, e.g., glaucoma, using such dsRNA compositions.
    Type: Application
    Filed: October 1, 2022
    Publication date: December 12, 2024
    Applicants: ALNYLAM PHARMACEUTICALS, INC., REGENERON PHARMACEUTIALS, INC.
    Inventors: JAMES D. MCININCH, VASANT R. JADHAV, BHAUMIK A. PANDYA, ELENA CASTELLANOS-RIZALDOS, ADAM CASTORENO, CARMELO ROMANO, GAURANG PATEL, YING HU
  • INTEGRIN TARGETING LIGANDS FOR OCULAR DELIVERY OF RNAI COMPOUNDS
    Publication number: 20240409927
    Abstract: The disclosure relates to RNA agents modified for targeted delivery to the eye. The present invention provides modified double stranded ribonucleic acid (dsRNAi) agents conjugated to an integrin targeting ligand, as well as methods of modulating the expression of a target gene in an ocular cell or tissue and methods of treating subjects having an ocular disease or disorder using such dsRNAi agents.
    Type: Application
    Filed: July 7, 2022
    Publication date: December 12, 2024
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: JAYAPRAKASH K. NAIR, ELENA CASTELLANOS-RIZALDOS, BHAUMIK A. PANDYA, VASANT R. JADHAV, JUAN SALINAS, KEVIN DOOLEY, SCOTT P. LENTINI, SHIGEO MATSUDA, MARK NEIL TOLENTINO
  • COMPOUNDS AND USES THEREOF
    Publication number: 20240400546
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: April 29, 2024
    Publication date: December 5, 2024
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Bertrand LE BOURDONNEC, Matthew LUCAS, Kerem OZBOYA, Bhaumik PANDYA, Parcharee TIVITMAHAISOON, Iwona WRONA
  • Compositions and Methods for Silencing MYOC Expression
    Publication number: 20240318175
    Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting MYOC, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of MYOC.
    Type: Application
    Filed: June 28, 2022
    Publication date: September 26, 2024
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: ADAM CASTORENO, BHAUMIK A. PANDYA, ELENA CASTELLANOS-RIZALDOS, MARK K. SCHLEGEL, VASANT R. JADHAV
  • Compounds and uses thereof
    Patent number: 12098146
    Abstract: The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: September 24, 2024
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Iwona Wrona, Kerem Ozboya, Matthew Lucas, Bhaumik Pandya, Bertrand Le Bourdonnec
  • HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE
    Publication number: 20240309003
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Application
    Filed: May 4, 2022
    Publication date: September 19, 2024
    Applicant: Vigil Neuroscience, Inc.
    Inventors: Jonathan B. HOUZE, Maxence BOS, John MANCUSO, Ivan FRANZONI, Bhaumik PANDYA, Alan KAPLAN
  • COMPOUNDS AND USES THEREOF
    Publication number: 20240300938
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: April 29, 2024
    Publication date: September 12, 2024
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Bertrand LE BOURDONNEC, Matthew LUCAS, Kerem OZBOYA, Bhaumik PANDYA, Parcharee TIVITMAHAISOON, Iwona WRONA
  • Compounds and uses thereof
    Patent number: 11970486
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: April 30, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Bertrand Le Bourdonnec, Matthew Lucas, Kerem Ozboya, Bhaumik Pandya, Parcharee Tivitmahaisoon, Iwona Wrona
  • COMPOUNDS AND USES THEREOF
    Publication number: 20240124435
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: September 27, 2023
    Publication date: April 18, 2024
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Matthew Lucas, Bertrand Le Bourdonnec, Iwona Wrona, Bhaumik Pandya, Parcharee Tivitmahaisoon, Kerem Ozboya, Benjamin Vincent, Daniel Tardiff, Jeff Piotrowski, Eric Solis, Robert Scannevin, Chee-Yeun Chung, Rebecca Aron, Kenneth Rhodes
  • Compounds and uses thereof
    Patent number: 11873298
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: January 16, 2024
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Matthew Lucas, Bertrand Le Bourdonnec, Iwona Wrona, Bhaumik Pandya, Parcharee Tivitmahaisoon, Kerem Ozboya, Benjamin Vincent, Daniel Tardiff, Jeff Piotrowski, Eric Solis, Robert Scannevin, Chee-Yeun Chung, Rebecca Aron, Kenneth Rhodes
  • DEUTERATED DERIVATIVES OF RUXOLITINIB
    Publication number: 20230355629
    Abstract: The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.
    Type: Application
    Filed: December 9, 2022
    Publication date: November 9, 2023
    Inventors: I. Robert Silverman, Julie F. Liu, Adam J. Morgan, Bhaumik Pandya, Scott L. Harbeson
  • COMPOSITIONS AND METHODS FOR SILENCING VEGF-A EXPRESSION
    Publication number: 20230136787
    Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting VEGF-A, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of VEGF-A.
    Type: Application
    Filed: February 9, 2021
    Publication date: May 4, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: JAMES D. MCININCH, MARK KEATING, MARK K. SCHLEGEL, ADAM CASTORENO, VASANT R. JADHAV, CHARALAMBOS KAITTANIS, ELENA CASTELLANOS-RIZALDOS, BHAUMIK A. PANDYA
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230116101
    Abstract: The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
    Type: Application
    Filed: November 13, 2020
    Publication date: April 13, 2023
    Inventors: Iwona WRONA, Kerem OZBOYA, Matthew LUCAS, Bhaumik PANDYA, Bertrand LE BOURDONNEC